First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology | Zendy

Christopher K. Dyke | Zendy; Steven R. Steinhubl | Zendy; Neal S. Kleiman | Zendy; Richard O. Can | Zendy; Laura G. Aberle | Zendy; Min Lin | Zendy; Shelley K. Myles | Zendy; Chiara Melloni | Zendy; Robert A. Harrington | Zendy; John H. Alexander | Zendy; Richard C. Becker | Zendy; Christopher P. Rusconi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology

Author(s) -

Christopher K. Dyke,

Steven R. Steinhubl,

Neal S. Kleiman,

Richard O. Can,

Laura G. Aberle,

Min Lin,

Shelley K. Myles,

Chiara Melloni,

Robert A. Harrington,

John H. Alexander,

Richard C. Becker,

Christopher P. Rusconi

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.668434

Subject(s) - medicine , antidote , aptamer , anticoagulant , rna , intensive care medicine , pharmacology , microbiology and biotechnology , biochemistry , gene , toxicity , chemistry , biology

Selectivity, titratability, rapidity of onset, and active reversibility are desirable pharmacological properties of anticoagulant therapy administered for acute indications and collectively represent an attractive platform to maximize patient safety. A novel anticoagulation system (REG1, Regado Biosciences), developed using a protein-binding oligonucleotide to factor IXa (drug, RB006) and its complementary oligonucleotide antidote (RB007), was evaluated in healthy volunteers. The primary objective was to determine the safety profile and to characterize the pharmacodynamic responses in this first-in-human study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research